Equities researchers at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Up 2.5 %
Shares of EVOK stock opened at $0.60 on Monday. Evoke Pharma has a 12 month low of $0.56 and a 12 month high of $2.42. The company has a quick ratio of 2.09, a current ratio of 2.25 and a debt-to-equity ratio of 9.29. The business’s 50 day moving average is $0.67 and its two-hundred day moving average is $1.00. The company has a market cap of $5.13 million, a PE ratio of -0.26 and a beta of 0.21.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The company had revenue of $1.68 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Stocks With Unusual Call Option Activity
- Bank Stocks – Best Bank Stocks to Invest In
- Trump Media & Technology Group Soars on Market Debut
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Stocks Insiders Are Buying That Analysts Love
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
